Evidence map›Paper›PMID 42144637›Full record

ArticleCardiovascular diabetology2026

Predicting cardiovascular death in overweight/obese people with prediabetes using machine learning-a proof-of-concept study.

Amalie K Andersen, Kristine Færch, Dorte Vistisen, Bernt J von Scholten, Nils B Jørgensen, Simon L Cichosz, Morten H Jensen

Abstract read
In one paragraph

Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amalie K AndersenMedical & Translational Science, Novo Nordisk A/S, Vandtårnsvej 108, 2860, Søborg, Denmark. amalieka@hst.aau.dk.
Kristine FærchDepartment of Health Science and Technology, Aalborg University, Selma Lagerløfsvej 249, 9260, Gistrup, Aalborg, Denmark.ORCID 0000-0002-6127-0448
Dorte VistisenMedical & Translational Science, Novo Nordisk A/S, Vandtårnsvej 108, 2860, Søborg, Denmark.ORCID 0000-0001-5045-5351
Bernt J von ScholtenMedical & Translational Science, Novo Nordisk A/S, Vandtårnsvej 108, 2860, Søborg, Denmark.ORCID 0000-0002-1489-0636
Nils B JørgensenMedical & Translational Science, Novo Nordisk A/S, Vandtårnsvej 108, 2860, Søborg, Denmark.ORCID 0000-0002-5764-6377
Simon L CichoszDepartment of Health Science and Technology, Aalborg University, Selma Lagerløfsvej 249, 9260, Gistrup, Aalborg, Denmark.ORCID 0000-0002-3484-7571
Morten H JensenMedical & Translational Science, Novo Nordisk A/S, Vandtårnsvej 108, 2860, Søborg, Denmark.ORCID 0000-0002-6649-8644

Funding

Danish Data Science Academy NNF21SA0069429Danish Diabetes and Endocrine Academy NNF22SA0079901
6 · The paper itself

Abstract

backgroundIndividuals with prediabetes face an increased risk of cardiovascular (CV) complications, which can ultimately lead to premature mortality. However, existing risk stratification tools are not targeted for people with prediabetes. We aimed to develop a simple explainable model to predict if a person will develop a fatal CV outcome or not among people with prediabetes.

methodsParticipants ≥ 45 years with prediabetes (HbA1c 39-47 mmol/mol (5.7-6.4%)) and established CV disease and overweight/obesity were included. A binary logistic regression model was trained to predict CV death using stratified threefold cross-validation. The model's risk estimates were calibrated, and the predictive capability was evaluated using receiver operating characteristic (ROC) area under the curve (AUC), precision and recall.

resultsIn total 5636 participants with 182 (3.2%) CV deaths (mean time-to-event of 2.0 years) and a mean trial duration of 3.3 years were included. Seven easily collected demographic and clinical variables were selected for the model. Discrimination (ROC AUC) was acceptable at 0.730 (95% CI 0.659-0.801). Applying our prediabetes cohort on existing benchmark models developed for major adverse cardiovascular events (MACE) in a general and type 2 diabetes population without prior CVD, demonstrated lower performance for CV death (ROC AUC: 0.630 (SCORE2) and 0.643 (SCORE2-Diabetes)) compared to our model. Lower performance was also observed for predicting MACE in our cohort (ROC AUC: 0.596 and 0.603) using the established models compared to the original populations (ROC AUC: 0.739 and 0.66-0.73). No comparative models for people with prediabetes and prior CVD exists. Thus, even with the limitations in different populations and outcome targets, this indicates that prediabetes-specific prediction models could potentially improve early prevention in this high-risk population.

conclusionWe have developed a prediabetes-specific proof-of-concept model that predicts whether a person is at high risk of cardiovascular death. External validation of the model is crucial before adoption to a real-world setting to clarify whether the model generalizes beyond the studied population.

Indexed as

Cardiovascular DiseasesDecision Support TechniquesObesityPrediabetic StatePredictive Learning ModelsAgedCause of DeathFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedPredictive Value of TestsPrognosisProof of Concept StudyReproducibility of ResultsCardiovascular deathExplainable AIMachine learningObesityPrediabetesPrediction modelling

Identifiers

PMID42144637
PMCPMC13348561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.